Investigation of the Mechanism of Impaired Skin Barrier Function in Dogs With Malignant Tumors

Background/Aim: No study has investigated skin barrier dysfunction with systemic diseases in veterinary medicine. We investigated the mechanism of disturbed skin barrier function in dogs with internal diseases. Materials and Methods: Healthy controls and dogs with systemic diseases were enrolled in three different disease groups: malignant tumor, hyperadrenocorticism and kidney disease. Transepidermal water loss (TEWL), serum levels of five selective pro-inflammatory cytokines and claudin-1, and complete blood count were measured. Results: TEWL was significantly increased in the malignant tumor group while serum claudin-1 concentrations were significantly lower compared to controls. Tumor necrosis factor-α was also significantly increased in the cancer group. In addition, the malignant tumor group showed significantly higher monocyte chemotactic protein-1 after chemotherapy, but lower interleukin-6 levels, compared to dogs with no chemotherapy. Conclusion: Skin barrier function was decreased in dogs with malignant tumors compared to dogs with other systemic diseases by oxidative stress and a reduction in tight junction proteins.

[1]  Kristina M. Ilieva,et al.  Basophils from Cancer Patients Respond to Immune Stimuli and Predict Clinical Outcome , 2020, Cells.

[2]  J. Brandner,et al.  Claudin-1 decrease impacts epidermal barrier function in atopic dermatitis lesions dose-dependently , 2020, Scientific Reports.

[3]  A. Akobeng,et al.  Claudin-1, A Double-Edged Sword in Cancer , 2020, International journal of molecular sciences.

[4]  J. Hamilton.  GM-CSF-Dependent Inflammatory Pathways , 2019, Front. Immunol..

[5]  M. Szczepanik,et al.  The influence of treatment with lokivetmab on transepidermal water loss (TEWL) in dogs with spontaneously occurring atopic dermatitis. , 2019, Veterinary dermatology.

[6]  K. Hiramoto,et al.  Impaired skin barrier function caused by reactive oxygen species in mice with colonic tumours , 2019, Cutaneous and ocular toxicology.

[7]  D. Santoro,et al.  Pilot study using five methods to evaluate skin barrier function in healthy dogs and in dogs with atopic dermatitis , 2019, Veterinary dermatology.

[8]  M. Simpson,et al.  The role of cellular reactive oxygen species in cancer chemotherapy , 2018, Journal of experimental & clinical cancer research : CR.

[9]  S. Kežić,et al.  A minimally invasive tool to study immune response and skin barrier in children with atopic dermatitis , 2018, The British journal of dermatology.

[10]  M. Man,et al.  Validation of GPSkin Barrier® for assessing epidermal permeability barrier function and stratum corneum hydration in humans , 2018, Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging.

[11]  M. Colombo,et al.  Mast cells, basophils and eosinophils: From allergy to cancer. , 2018, Seminars in immunology.

[12]  J. Cerón,et al.  MCP-1, KC-like and IL-8 as critical mediators of pathogenesis caused by Babesia canis , 2018, PloS one.

[13]  H. Gunawan,et al.  Cutaneous Side Effects and Transepidermal Water Loss To Gefitinib: A Study of 11 Patients , 2016, Dermatology and Therapy.

[14]  G. Wood,et al.  Comparison of serum cytokine levels between dogs with multicentric lymphoma and healthy dogs. , 2016, Veterinary immunology and immunopathology.

[15]  K. Hiramoto,et al.  Chronic liver injury in mice promotes impairment of skin barrier function via tumor necrosis factor-alpha , 2016, Cutaneous and ocular toxicology.

[16]  Charles W. Bradley,et al.  Longitudinal Evaluation of the Skin Microbiome and Association with Microenvironment and Treatment in Canine Atopic Dermatitis. , 2016, The Journal of investigative dermatology.

[17]  F. Södersten,et al.  Multiplex cytokine analyses in dogs with pyometra suggest involvement of KC-like chemokine in canine bacterial sepsis. , 2016, Veterinary immunology and immunopathology.

[18]  A. Sahebkar,et al.  Interleukin-6: A Critical Cytokine in Cancer Multidrug Resistance. , 2016, Current pharmaceutical design.

[19]  S. Biswas.  Does the Interdependence between Oxidative Stress and Inflammation Explain the Antioxidant Paradox? , 2016, Oxidative medicine and cellular longevity.

[20]  K. Hiramoto,et al.  Impairment of skin barrier function via cholinergic signal transduction in a dextran sulphate sodium‐induced colitis mouse model , 2015, Experimental dermatology.

[21]  V. Morsch,et al.  Oxidative stress and inflammatory response biomarkers in dogs with mammary carcinoma. , 2015, Pathology, research and practice.

[22]  K. Hiramoto,et al.  Impaired skin barrier function in mice with colon carcinoma induced by azoxymethane and dextran sodium sulfate. , 2015, Biological & pharmaceutical bulletin.

[23]  M. Szczepanik,et al.  Assessment of the relationship between transepidermal water loss (TEWL) and severity of clinical signs (CADESI-03) in atopic dogs. , 2014, Veterinary dermatology.

[24]  N. Cohen,et al.  Cerebrospinal fluid inflammatory cytokines and chemokines in naturally occurring canine spinal cord injury. , 2014, Journal of neurotrauma.

[25]  K. Hiramoto,et al.  Skin disruption is associated with indomethacin‐induced small intestinal injury in mice , 2014, Experimental dermatology.

[26]  M. Szczepańska,et al.  Disturbed skin barrier in children with chronic kidney disease , 2014, Pediatric Nephrology.

[27]  M. Kjelgaard‐Hansen,et al.  Monocyte chemotactic protein-1 and other inflammatory parameters in Bernese Mountain dogs with disseminated histiocytic sarcoma. , 2013, Veterinary journal.

[28]  B. Lüscher,et al.  Cytokines and the Skin Barrier , 2013, International journal of molecular sciences.

[29]  J. Davis,et al.  Effects of 5-fluorouracil chemotherapy on fatigue: Role of MCP-1 , 2013, Brain, Behavior, and Immunity.

[30]  R. Marsella.  Are transepidermal water loss and clinical signs correlated in canine atopic dermatitis? A compilation of studies. , 2012, Veterinary dermatology.

[31]  Gabriella Fabbrocini,et al.  Chemotherapy and skin reactions , 2012, Journal of experimental & clinical cancer research : CR.

[32]  T. Olivry.  Is the skin barrier abnormal in dogs with atopic dermatitis? , 2011, Veterinary immunology and immunopathology.

[33]  D. Thamm,et al.  Increased monocyte chemotactic protein-1 concentration and monocyte count independently associate with a poor prognosis in dogs with lymphoma. , 2011, Veterinary and comparative oncology.

[34]  M. Geller,et al.  Chemotherapy Induces Macrophage Chemoattractant Protein-1 Production in Ovarian Cancer , 2010, International Journal of Gynecologic Cancer.

[35]  C. Chesney,et al.  Evaluation of a hand-held evaporimeter (VapoMeter) for the measurement of transepidermal water loss in healthy dogs. , 2010, Veterinary dermatology.

[36]  Taeho Oh,et al.  Measurement of transepidermal water loss from clipped and unclipped anatomical sites on the dog. , 2009, Australian veterinary journal.

[37]  K. Nishifuji,et al.  Increased transepidermal water loss and decreased ceramide content in lesional and non-lesional skin of dogs with atopic dermatitis. , 2009, Veterinary dermatology.

[38]  E. Topham.  Cutaneous manifestations of cancer and chemotherapy. , 2009, Clinical medicine.

[39]  S. Amini,et al.  Monocyte chemoattractant protein-1 (MCP-1): an overview. , 2009, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[40]  Y. Chan,et al.  Skin barrier structure and function and their relationship to pruritus in end-stage renal disease. , 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[41]  Peter M. Elias,et al.  The skin barrier as an innate immune element , 2007, Seminars in Immunopathology.

[42]  Y. Soini.  Expression of claudins 1, 2, 3, 4, 5 and 7 in various types of tumours , 2005, Histopathology.

[43]  B. Rollins,et al.  CCL2 (monocyte chemoattractant protein-1) and cancer. , 2004, Seminars in cancer biology.

[44]  P. Elias,et al.  Cutaneous barrier perturbation stimulates cytokine production in the epidermis of mice. , 1992, The Journal of clinical investigation.

[45]  A. Ngezahayo,et al.  Claudin-1, -3, -4 and -7 gene expression analyses in canine prostate carcinoma and mammary tissue derived cell lines. , 2016, Neoplasma.

[46]  I. Amorim,et al.  Altered expression of claudin-1 is related with malignancy in canine thyroid tumors. , 2015, In vivo.

[47]  L. Ding,et al.  The claudin family of proteins in human malignancy : a clinical perspective , 2013 .

[48]  C. Outerbridge.  Cutaneous manifestations of internal diseases. , 2013, The Veterinary clinics of North America. Small animal practice.

[49]  J. Kulka,et al.  Expression of claudin-1, -3, -4, -5 and -7 proteins in low grade colorectal carcinoma of canines. , 2010, Histology and histopathology.